Selected research
Market Structure
Global Inactivated Poliovirus Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Inactivated Poliovirus Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Inactivated Poliovirus Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Inactivated Poliovirus Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Inactivated Poliovirus Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Inactivated Poliovirus Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Inactivated Poliovirus Vaccine include Sanofi, GSK, Serum Institute (Bilthoven Biologicals) and IMBCA, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Inactivated Poliovirus Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Inactivated Poliovirus Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Inactivated Poliovirus Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Inactivated Poliovirus Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.
Inactivated Poliovirus Vaccine Segment by Company
Sanofi
GSK
Serum Institute (Bilthoven Biologicals)
IMBCA
Inactivated Poliovirus Vaccine Segment by Type
Human Diploid Cell
Monkey Kidney Cell
Inactivated Poliovirus Vaccine Segment by Application
Public
Private
Inactivated Poliovirus Vaccine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Inactivated Poliovirus Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Inactivated Poliovirus Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Inactivated Poliovirus Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Inactivated Poliovirus Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Inactivated Poliovirus Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Inactivated Poliovirus Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Inactivated Poliovirus Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Human Diploid Cell
- Monkey Kidney Cell
Applications
- Public
- Private
Companies covered
- Sanofi
- GSK
- Serum Institute (Bilthoven Biologicals)
- IMBCA
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Inactivated Poliovirus Vaccine Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Inactivated Poliovirus Vaccine Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Inactivated Poliovirus Vaccine Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Inactivated Poliovirus Vaccine Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Inactivated Poliovirus Vaccine Market Dynamics
- 2.1 Inactivated Poliovirus Vaccine Industry Trends
- 2.2 Inactivated Poliovirus Vaccine Industry Drivers
- 2.3 Inactivated Poliovirus Vaccine Industry Opportunities and Challenges
- 2.4 Inactivated Poliovirus Vaccine Industry Restraints
3 Inactivated Poliovirus Vaccine Market by Manufacturers
- 3.1 Global Inactivated Poliovirus Vaccine Revenue by Manufacturers (2021-2026)
- 3.2 Global Inactivated Poliovirus Vaccine Sales by Manufacturers (2021-2026)
- 3.3 Global Inactivated Poliovirus Vaccine Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Inactivated Poliovirus Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Inactivated Poliovirus Vaccine Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Inactivated Poliovirus Vaccine Manufacturers, Product Type & Application
- 3.7 Global Inactivated Poliovirus Vaccine Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Inactivated Poliovirus Vaccine Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Inactivated Poliovirus Vaccine Players Market Share by Revenue in 2025
- 3.8.3 2025 Inactivated Poliovirus Vaccine Tier 1, Tier 2, and Tier 3
4 Inactivated Poliovirus Vaccine Market by Type
- 4.1 Inactivated Poliovirus Vaccine Type Introduction
- 4.1.1 Human Diploid Cell
- 4.1.2 Monkey Kidney Cell
- 4.2 Global Inactivated Poliovirus Vaccine Sales by Type
- 4.2.1 Global Inactivated Poliovirus Vaccine Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Inactivated Poliovirus Vaccine Sales by Type (2021-2032)
- 4.2.3 Global Inactivated Poliovirus Vaccine Sales Market Share by Type (2021-2032)
- 4.3 Global Inactivated Poliovirus Vaccine Revenue by Type
- 4.3.1 Global Inactivated Poliovirus Vaccine Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Inactivated Poliovirus Vaccine Revenue by Type (2021-2032)
- 4.3.3 Global Inactivated Poliovirus Vaccine Revenue Market Share by Type (2021-2032)
5 Inactivated Poliovirus Vaccine Market by Application
- 5.1 Inactivated Poliovirus Vaccine Application Introduction
- 5.1.1 Public
- 5.1.2 Private
- 5.2 Global Inactivated Poliovirus Vaccine Sales by Application
- 5.2.1 Global Inactivated Poliovirus Vaccine Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Inactivated Poliovirus Vaccine Sales by Application (2021-2032)
- 5.2.3 Global Inactivated Poliovirus Vaccine Sales Market Share by Application (2021-2032)
- 5.3 Global Inactivated Poliovirus Vaccine Revenue by Application
- 5.3.1 Global Inactivated Poliovirus Vaccine Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Inactivated Poliovirus Vaccine Revenue by Application (2021-2032)
- 5.3.3 Global Inactivated Poliovirus Vaccine Revenue Market Share by Application (2021-2032)
6 Global Inactivated Poliovirus Vaccine Sales by Region
- 6.1 Global Inactivated Poliovirus Vaccine Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Inactivated Poliovirus Vaccine Sales by Region (2021-2032)
- 6.2.1 Global Inactivated Poliovirus Vaccine Sales by Region (2021-2026)
- 6.2.2 Global Inactivated Poliovirus Vaccine Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Inactivated Poliovirus Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Inactivated Poliovirus Vaccine Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Inactivated Poliovirus Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Inactivated Poliovirus Vaccine Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Inactivated Poliovirus Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Inactivated Poliovirus Vaccine Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Inactivated Poliovirus Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Inactivated Poliovirus Vaccine Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Inactivated Poliovirus Vaccine Revenue by Region
- 7.1 Global Inactivated Poliovirus Vaccine Revenue by Region
- 7.1.1 Global Inactivated Poliovirus Vaccine Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Inactivated Poliovirus Vaccine Revenue by Region (2021-2026)
- 7.1.3 Global Inactivated Poliovirus Vaccine Revenue by Region (2027-2032)
- 7.1.4 Global Inactivated Poliovirus Vaccine Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Inactivated Poliovirus Vaccine Revenue (2021-2032)
- 7.2.2 North America Inactivated Poliovirus Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Inactivated Poliovirus Vaccine Revenue (2021-2032)
- 7.3.2 Europe Inactivated Poliovirus Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Inactivated Poliovirus Vaccine Revenue (2021-2032)
- 7.4.2 Asia-Pacific Inactivated Poliovirus Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Inactivated Poliovirus Vaccine Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Inactivated Poliovirus Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Sanofi
- 8.1.1 Sanofi Company Information
- 8.1.2 Sanofi Business Overview
- 8.1.3 Sanofi Inactivated Poliovirus Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Sanofi Inactivated Poliovirus Vaccine Product Portfolio
- 8.1.5 Sanofi Recent Developments
- 8.2 GSK
- 8.2.1 GSK Company Information
- 8.2.2 GSK Business Overview
- 8.2.3 GSK Inactivated Poliovirus Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 GSK Inactivated Poliovirus Vaccine Product Portfolio
- 8.2.5 GSK Recent Developments
- 8.3 Serum Institute (Bilthoven Biologicals)
- 8.3.1 Serum Institute (Bilthoven Biologicals) Company Information
- 8.3.2 Serum Institute (Bilthoven Biologicals) Business Overview
- 8.3.3 Serum Institute (Bilthoven Biologicals) Inactivated Poliovirus Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Serum Institute (Bilthoven Biologicals) Inactivated Poliovirus Vaccine Product Portfolio
- 8.3.5 Serum Institute (Bilthoven Biologicals) Recent Developments
- 8.4 IMBCA
- 8.4.1 IMBCA Company Information
- 8.4.2 IMBCA Business Overview
- 8.4.3 IMBCA Inactivated Poliovirus Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 IMBCA Inactivated Poliovirus Vaccine Product Portfolio
- 8.4.5 IMBCA Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Inactivated Poliovirus Vaccine Value Chain Analysis
- 9.1.1 Inactivated Poliovirus Vaccine Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Inactivated Poliovirus Vaccine Production Mode & Process
- 9.2 Inactivated Poliovirus Vaccine Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Inactivated Poliovirus Vaccine Distributors
- 9.2.3 Inactivated Poliovirus Vaccine Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst